HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality - Wikidata - awgldk - TriplyDB

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

http://www.wikidata.org/entity/Q27488220

about

Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes Chronic hepatitis C and liver fibrosis.Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya Causal inference regarding infectious aetiology of chronic conditions: a systematic review.Economic assessment of eltrombopag in the treatment of thrombocytopenia.Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Update on epidemiology of HCV in Italy: focus on the Calabria Region.Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.No strategy to meet the HCV epidemic Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells Clinical utility of pharmacogenomics in the management of hepatitis C.The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.Current and future disease progression of the chronic HCV population in the United States.Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Labour productivity losses caused by premature death associated with hepatitis C in Spain.Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey.HCV Infection Frequency and Trends Among Voluntary Blood Donors in Cluj County (Romania) Between 2006 and 2011.Viral Evolved Inhibition Mechanism of the RNA Dependent Protein Kinase PKR's Kinase Domain, a Structural Perspective.Predictors for Early Identification of Hepatitis C Virus Infection Exposure to hepatitis C virus in homeless men in Central Brazil: a cross-sectional study.A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada Chronic hepatitis C in saudi arabia: three years local experience in a university hospital.Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis Neutralizing antibodies and pathogenesis of hepatitis C virus infection.Nonprimate hepaciviruses in domestic horses, United kingdom Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives.Accuracy of physician reporting in routine public health surveillance for hepatitis C virus infection.Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt.Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey Acute hepatitis C: management in the rapidly evolving world of HCV.The cost-effectiveness of boceprevir for hepatitis C.Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal.High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening.

P2860

Q26781991-37A598A1-6578-41A6-81A0-94F7683FD3D0 Q26825671-80316516-D1AC-426B-851C-410E33DFE601 Q28079580-66B0126E-20A2-4ED5-8707-EF018A4A8200 Q28539749-E2D7E464-47A8-4E10-B118-CE946B9542D9 Q31126057-EF7E085C-8800-42F6-B652-326DB3EC70E4 Q33424436-8B2EEAB7-B40A-4F96-A5CC-0DDC9FF13C3B Q33559091-64825CD1-EC14-4A33-AF1D-CB9D6B146289 Q33563427-3599B1F3-051B-4923-A48E-82E5F2698FD3 Q34143327-D71F4958-4AD8-46B5-80E2-0F2A2146A3BC Q34163400-F1DF1CE3-8B7E-4B65-965A-573601CB1D57 Q34260584-3928CDC1-C261-463A-8FB2-0DF95CFE5E30 Q34260680-967640AD-0CCB-4619-882B-9AB2DC1438B4 Q34446790-878A1232-0A4D-41F7-9D27-BA47299FFCD2 Q34464613-5873841B-FD3F-44B9-997E-8E85925A1229 Q34550098-68BB2B01-5AAD-4837-B7EF-C8EC31F2E0C5 Q34677180-F409A3C9-CA93-42A4-BDBE-E228C7C7ED49 Q34737843-C513926E-2F44-409D-881F-69893B05797B Q34923455-28DC8BEF-51E8-4576-A7AB-7538EAC94220 Q35205389-0838090B-A17D-4091-BF41-67C31CB8DDA5 Q35558268-0265CC31-BE7A-475C-BCFA-AB3B4EFFFAE1 Q35749620-A8425772-107B-4640-BDD6-1AEFBB76798A Q35869066-81367506-890A-4AA5-810E-C502F9525583 Q35992377-6E6615C1-F875-4D0C-91C8-33E0BC09AF2B Q36043559-59798208-F299-44C9-9986-47DC1C1FDAF4 Q36253099-DEEA1711-D7FA-47CA-92D3-41E736E8D783 Q36279118-039621FA-D4D6-4813-8840-52214861FBB5 Q36329009-1B5A69F3-1DD5-4AF9-860C-9AE25E04C134 Q36386177-4F116EFD-D965-4E4F-BAC8-C3A36BA8DB29 Q36395837-7662BB8D-DA35-4931-8011-57DD3478DE80 Q36570546-BD039A53-F6D7-4F91-B554-2EC9FC38C344 Q37170571-C24D100A-3863-4DB4-AF1A-337839005E2F Q37391715-06BC8EE9-5ACC-4B55-87B2-D709002AF6FA Q37401168-7F07A924-3A1B-400F-8D36-8D36AC37E101 Q37485037-4A046EFD-B444-42E2-B8DF-BB3188974EA3 Q38183312-782AD05F-FC15-48CC-999D-6EB1BFEAB6A4 Q38202682-6955A284-48B5-4380-AC85-470673F13ADB Q38249236-85601904-44D1-4474-9654-5116B2CDAD97 Q38642932-CAF16271-9E72-49E1-A3D7-E22545BE333C Q38929061-2056BBE7-2DC5-48D5-BF90-43C2C0C77F49 Q38964724-2B8070B7-2E6D-4790-90AF-3569082237DF

P2860

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

http://www.wikidata.org/entity/Q27488220

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

HCV-related burden of disease ...... ence, morbidity, and mortality

@ast

HCV-related burden of disease ...... ence, morbidity, and mortality

@en

HCV-related burden of disease ...... ence, morbidity, and mortality

@nl

type

label

HCV-related burden of disease ...... ence, morbidity, and mortality

@ast

HCV-related burden of disease ...... ence, morbidity, and mortality

@en

HCV-related burden of disease ...... ence, morbidity, and mortality

@nl

prefLabel

HCV-related burden of disease ...... ence, morbidity, and mortality

@ast

HCV-related burden of disease ...... ence, morbidity, and mortality

@en

HCV-related burden of disease ...... ence, morbidity, and mortality

@nl

P1433

Q27488220-DCDA7874-C7BB-42D9-AAB3-758D90FDA908

P1476

Q27488220-702D7276-93B0-4691-A462-53864A42C311

P2093

Q27488220-5A750B6C-4E51-482C-9F42-24BC10F3CBD8

Q27488220-8EC9F6A2-62D3-4FF3-AD2F-E0E3D74FAFED

Q27488220-8F65BA79-606D-4505-98F8-7ECDFBA3CF7F

Q27488220-C4210680-3CBF-46EB-B89C-01ADA918F3D0

Q27488220-DF11909A-0B21-48B5-9E0F-682ACBA17B47

P275

Q27488220-27C77E9F-C5CB-4E43-AD08-1126964F169E

P2860

Q27488220-035C400A-D56E-4C5B-B556-59064037E792

Q27488220-050AADDC-D029-48AF-9A34-59BBD7525D26

Q27488220-08124985-710A-46AC-8C91-6571EF7FA04C

Q27488220-0CCB7792-4D0E-40D1-9EA1-3710C5909AC5

Q27488220-0D0C3521-4CC5-4F4A-B889-664145895582

Q27488220-0EDE9CD5-A941-4582-BCE6-E1BF27D79F23

Q27488220-15B66BEE-C71D-414C-B311-6572076E25E0

Q27488220-19ECF771-4F64-4770-8F00-F5BDC9836008

Q27488220-1B349290-16DA-4392-A014-281B443FE39B

Q27488220-236E964A-04C3-498E-AA49-58012DBDC3BA

P2888

Q27488220-50A5D1D1-F5CB-4E41-96B2-F5747FED7864

P304

Q27488220-3EDA70AB-617F-4A3F-983A-8194CBB1F694

P31

Q27488220-7D567861-FD97-4A89-8593-46A27426D42F

Q27488220-B22C19D0-4046-4E11-9F4A-17F6DF46CA6B

P3181

Q27488220-D7AA488D-E6C0-4BAB-BD03-155AA6060117

P356

Q27488220-AD60FFEC-3CB3-42A2-9505-722189444F78

P407

Q27488220-E823B84E-D759-484E-B24D-7DA614F339AD

P433

Q27488220-201520F1-F761-4AD2-9AE8-531E37523179

P478

Q27488220-D71D9EC8-10EA-4638-8521-A0FC4F1DB614

P50

Q27488220-7467733A-A0E4-409B-B80A-CDA659BF148C

P5008

Q27488220-2EE468FA-5C24-4BA3-9A0D-FB23D35EEFE2

P577

Q27488220-8F2C8C94-BEFE-4716-B1A7-388910E5BC42

P5875

Q27488220-598FE5CE-B1A5-4425-849F-A66EBEBE6AE2

P6179

Q27488220-C7998569-F1D5-4F67-880F-7B7D4EAE12CD

P698

Q27488220-1C0D4F69-AC9F-456A-B687-2541B37BF266

P921

Q27488220-33D71B72-7F0E-4969-9896-866C3ECDC8EC

Q27488220-4B06146C-998C-42A3-ABE0-3AE275879F11

Q27488220-6087AAB1-85C1-4C84-921B-EAA71E340625

Q27488220-647AAF8A-0064-43C8-A82F-649A31D9DB46

Q27488220-71AC86C4-D45A-4AB7-B11A-7F327EB5BAE8

P932

Q27488220-13F07DFB-9821-4BC6-9AA8-22A5F8A15FCC

P3181

P356

P1433

BMC Public Health

P1476

HCV-related burden of disease ...... ence, morbidity, and mortality

@en

P2093

Beate Lettmeier

http://www.w3.org/2001/XMLSchema#string

Gaby Sroczynski

http://www.w3.org/2001/XMLSchema#string

Nikolai Mühlberger

http://www.w3.org/2001/XMLSchema#string

Ruth Schwarzer

http://www.w3.org/2001/XMLSchema#string

Uwe Siebert

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

The natural history of hepatitis C virus (HCV) infection.

Global epidemiology of hepatitis C virus infection

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Hepatitis C virus infection

Quantifying the burden of disease: the technical basis for disability-adjusted life years

The global health burden of infection-associated cancers in the year 2002

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Mortality by cause for eight regions of the world: Global Burden of Disease Study

P2888

P304

34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2260054

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1471-2458-9-34

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2009-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23930792

http://www.w3.org/2001/XMLSchema#string

P6179

1034910187

http://www.w3.org/2001/XMLSchema#string

P698

19161623

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

2656539

http://www.w3.org/2001/XMLSchema#string